CVT-10216,
GS 455534,
CVT-10216,
1005334-57-5,
CVT 10216,
UNII-F9H432757X,
3-(((3-(4-(METHYLSULFONAMIDO)PHENYL)-4-OXO-4H-CHROMEN-7-YL)OXY)METHYL)BENZOIC ACID,
F9H432757X,
3-[[[3-[4-[(Methylsulfonyl)amino]phenyl]-4-oxo-4H-1-benzopyran-7-yl]oxy]methyl]benzoic acid,
YYOOFJZTRCPVFD-UHFFFAOYSA-N,
SCHEMBL2107596,
EX-A311,
BCP27995,
ZINC43172134,
AKOS025142057,
3-(((3-(4-((Methylsulfonyl)amino)phenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)benzoic acid,
Benzoic acid, 3-(((3-(4-((methylsulfonyl)amino)phenyl)-4-oxo-4H-1-benzopyran-7-yl)oxy)methyl)-,
DA-48426,
CVT-10216 solution, 100 mM in DMSO,
FT-0737831,
CVT-10216, >=98% (HPLC),
1005334-57-5 solution, 100 mM in DMSO,
3-[(3-{4-[(methylsulfonyl)amino]phenyl}-4-oxochromen-7-yloxy)methyl]benzoic acid,
3-(((3-(4-(methylsulfonamido)phenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)benzoic acid solution, 100 mM in DMSO,
D0W4WP,
CVT-10083,
CVT-10200,
CVT-10992,
GS 455534,
B4928,
ALDH2 antagonists (alcoholism), CV Therapeutics,
ALDH2 antagonists (alcoholism), Gilead Palo Alto,
C550386,
Aldehyde dehydrogenase-2 antagonists (alcoholism), CV Therapeutics,
3-(((3-(4-(METHYLSULFONAMIDO)PHENYL)-4-OXO-4H-CHROMEN-7-YL)OXY)METHYL)BENZO IC ACID,